Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spero Therapeutics, Inc. - Common Stock
(NQ:
SPRO
)
2.570
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Spero Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Mid-Morning Market Update: Markets Mixed; Dow Drops 50 Points
↗
May 03, 2022
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 50 points on Tuesday.
Via
Benzinga
FDA Identifies Review Issues For Spero's Tebipenem Application, Shares Plunge
↗
May 03, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
↗
May 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 03, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
February 23, 2022
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
February 04, 2022
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
April 04, 2022
On Monday, 78 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: Citigroup (NYSE:C) was the biggest company by market cap to set a new 52-week low....
Via
Benzinga
38 Stocks Moving In Friday's Mid-Day Session
↗
April 01, 2022
Gainers Manning & Napier, Inc. (NYSE: MN) jumped 40.7% to $12.82 after the company reported it will be acquired by Callodine Group and will go private at $12.85 per share....
Via
Benzinga
55 Biggest Movers From Friday
↗
April 04, 2022
Gainers Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday. Chicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE) rose 43.8% to settle at $11.49...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 01, 2022
Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market value of their outstanding shares is at $18.4...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
April 01, 2022
On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (...
Via
Benzinga
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
↗
April 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
↗
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
A Preview Of Spero Therapeutics's Earnings
↗
March 30, 2022
Spero Therapeutics (NASDAQ:SPRO) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Spero...
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
↗
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Earnings Scheduled For March 31, 2022
↗
March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Via
Benzinga
Why Jim Cramer Like NextEra Energy And Lincoln Electric?
↗
January 21, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said NextEra Energy, Inc. (NYSE:
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
↗
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
4 Stocks Insiders Are Buying
↗
January 13, 2022
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...
Via
Benzinga
FDA Lifts Clinical Hold On Spero Therapeutics' Lung Infection Program
↗
January 04, 2022
The FDA has lifted the clinical hold on Spero Therapeutics Inc's (NASDAQ: SPRO) Phase 2 trial of SPR720 for nontuberculous mycobacterial (NTM) disease....
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
March 08, 2022
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
February 18, 2022
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
February 08, 2022
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
January 03, 2022
Gainers Genprex (NASDAQ:GNPX) stock moved upwards by 117.5% to $2.85 during Monday's regular session. Genprex's stock is trading at a volume of 101.5 million...
Via
Benzinga
The Past Week's Notable Insider Buys Included Asana, Designer Brands, Evergy And More
↗
October 09, 2021
Insider buying can be an encouraging signal for potential investors, especially when markets are uncertain. The week's most notable insider purchases were made by returning...
Via
Benzinga
3 Stocks Insiders Are Buying
↗
October 05, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
Spero Therapeutics Inks Revenue Interest Financing Agreement With HealthCare Royalty Partners
↗
September 30, 2021
Spero Therapeutics Inc (NASDAQ: SPRO) has entered into a revenue interest financing agreement with HealthCare Royalty Partners for up to $125 million. Spero...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021
↗
October 01, 2021
Upgrades Northland Capital Markets upgraded the previous rating for Five9 Inc (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.